These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 23023563)

  • 1. In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer.
    Shen HC; Shanmugasundaram K; Simon NI; Cai C; Wang H; Chen S; Balk SP; Rigby AC
    Mol Endocrinol; 2012 Nov; 26(11):1836-46. PubMed ID: 23023563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
    Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
    Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
    Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An androgen receptor N-terminal domain antagonist for treating prostate cancer.
    Myung JK; Banuelos CA; Fernandez JG; Mawji NR; Wang J; Tien AH; Yang YC; Tavakoli I; Haile S; Watt K; McEwan IJ; Plymate S; Andersen RJ; Sadar MD
    J Clin Invest; 2013 Jul; 123(7):2948-60. PubMed ID: 23722902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.
    Guerrero J; Alfaro IE; Gómez F; Protter AA; Bernales S
    Prostate; 2013 Sep; 73(12):1291-305. PubMed ID: 23765603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ligand-independent and tissue-selective androgen receptor inhibition by pyrvinium.
    Lim M; Otto-Duessel M; He M; Su L; Nguyen D; Chin E; Alliston T; Jones JO
    ACS Chem Biol; 2014 Mar; 9(3):692-702. PubMed ID: 24354286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy.
    Siddique HR; Mishra SK; Karnes RJ; Saleem M
    Clin Cancer Res; 2011 Aug; 17(16):5379-91. PubMed ID: 21712449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor.
    Yu Z; Cai C; Gao S; Simon NI; Shen HC; Balk SP
    Clin Cancer Res; 2014 Aug; 20(15):4075-85. PubMed ID: 24874833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new avenue toward androgen receptor pan-antagonists: C2 sterically hindered substitution of hydroxy-propanamides.
    Guerrini A; Tesei A; Ferroni C; Paganelli G; Zamagni A; Carloni S; Di Donato M; Castoria G; Leonetti C; Porru M; De Cesare M; Zaffaroni N; Beretta GL; Del Rio A; Varchi G
    J Med Chem; 2014 Sep; 57(17):7263-79. PubMed ID: 25121586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.
    Lallous N; Leblanc E; Munuganti RS; Hassona MD; Nakouzi NA; Awrey S; Morin H; Roshan-Moniri M; Singh K; Lawn S; Yamazaki T; Adomat HH; Andre C; Daugaard M; Young RN; Guns ES; Rennie PS; Cherkasov A
    Mol Cancer Ther; 2016 Dec; 15(12):2936-2945. PubMed ID: 27765852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.
    Rosati R; Polin L; Ducker C; Li J; Bao X; Selvakumar D; Kim S; Xhabija B; Larsen M; McFall T; Huang Y; Kidder BL; Fribley A; Saxton J; Kakuta H; Shaw P; Ratnam M
    Clin Cancer Res; 2018 Dec; 24(24):6509-6522. PubMed ID: 30185422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer.
    Sadar MD
    World J Urol; 2012 Jun; 30(3):311-8. PubMed ID: 21833557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists.
    Yamamoto S; Kobayashi H; Kaku T; Aikawa K; Hara T; Yamaoka M; Kanzaki N; Hasuoka A; Baba A; Ito M
    Bioorg Med Chem; 2013 Jan; 21(1):70-83. PubMed ID: 23199477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer.
    Ponnusamy S; He Y; Hwang DJ; Thiyagarajan T; Houtman R; Bocharova V; Sumpter BG; Fernandez E; Johnson D; Du Z; Pfeffer LM; Getzenberg RH; McEwan IJ; Miller DD; Narayanan R
    Clin Cancer Res; 2019 Nov; 25(22):6764-6780. PubMed ID: 31481513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.
    Dalal K; Roshan-Moniri M; Sharma A; Li H; Ban F; Hessein M; Hsing M; Singh K; LeBlanc E; Dehm S; Tomlinson Guns ES; Cherkasov A; Rennie PS
    J Biol Chem; 2014 Sep; 289(38):26417-26429. PubMed ID: 25086042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer.
    Lv S; Song Q; Chen G; Cheng E; Chen W; Cole R; Wu Z; Pascal LE; Wang K; Wipf P; Nelson JB; Wei Q; Huang W; Wang Z
    J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33332287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity.
    Sadar MD
    Cancer Res; 2011 Feb; 71(4):1208-13. PubMed ID: 21285252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
    Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
    Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor antagonists in castration-resistant prostate cancer.
    Rathkopf D; Scher HI
    Cancer J; 2013; 19(1):43-9. PubMed ID: 23337756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer.
    Mohler ML; Sikdar A; Ponnusamy S; Hwang DJ; He Y; Miller DD; Narayanan R
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.